Intravenous perfluoropropane-exposed sonicated dextrose albumin produces myocardial ultrasound contrast that correlates with coronary blood flow

DOI: 10.1016/s0894-7317(05)80386-4
Journal of the American Society of Echocardiography, 1995, 8, 710-8.

#	Paper	IF	Citations
56	Noninvasive identification of acute myocardial ischemia and reperfusion with contrast ultrasound using intravenous perfluoropropane-exposed sonicated dextrose albumin. *Journal of the American College of Cardiology*, **1995**, 26, 33-40	15.1	77
55	Reduction in left ventricular cavitary attenuation and improvement in posterior myocardial contrast with higher molecular weight intravenous perfluorocarbon-exposed sonicated dextrose albumin microbubbles. *Journal of the American Society of Echocardiography*, **1996**, 9, 437-41	5.8	20
54	Detection of myocardial perfusion abnormalities during dobutamine and adenosine stress echocardiography with transient myocardial contrast imaging after minute quantities of intravenous perfluorocarbon-exposed sonicated dextrose albumin. *Journal of the American Society of Echocardiography*, **1996**, 9, 779-86	5.8	28
53	Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose albumin microbubbles. *American Heart Journal*, **1996**, 132, 964-8	4.9	145
52	Myocardial perfusion abnormalities during low-dose dobutamine after coronary reperfusion can be demonstrated with intravenous perfluorocarbon-exposed sonicated dextrose albumin ultrasound contrast. *American Heart Journal*, **1996**, 131, 1079-87	4.9	8
51	Detection of regional perfusion abnormalities during adenosine stress echocardiography with intravenous perfluorocarbon-exposed sonicated dextrose albumin. *American Heart Journal*, **1996**, 132, 41-7	4.9	14
50	Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection. *Journal of the American College of Cardiology*, **1996**, 28, 1292-300	15.1	128
49	Echo-enhancing agents: their physics and pharmacology. **1997**, 85-113		4
48	Safety and efficacy of QW7437, a new fluorocarbon-based echocardiographic contrast agent. *Journal of the American Society of Echocardiography*, **1997**, 10, 798-804	5.8	25
47	Benefits of reducing the cardiac cycle-triggering frequency of ultrasound imaging to increase myocardial opacification with FSO69 during fundamental and second harmonic imaging. *Journal of the American Society of Echocardiography*, **1997**, 10, 602-7	5.8	35
46	Contrast echocardiography: influence of ultrasonic machine settings, mixing conditions, and pressurization on pixel intensity and microsphere size of Albunex solutions in vitro. *Journal of the American Society of Echocardiography*, **1997**, 10, 31-40	5.8	9
45	Contrast echocardiography: review and future directions. *American Journal of Cardiology*, **1998**, 81, 41G-48G	3	43
44	New ultrasound contrast agents for left ventricular and myocardial opacification. *Herz*, **1998**, 23, 474-82	2.6	16
43	Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. *Journal of the American College of Cardiology*, **1998**, 32, 1756-64	15.1	256
42	Noninvasive in vivo clot dissolution without a thrombolytic drug: recanalization of thrombosed iliofemoral arteries by transcutaneous ultrasound combined with intravenous infusion of microbubbles. *Circulation*, **1998**, 97, 130-4	16.7	148
41	The influence of different gases on acoustic properties of a spherosome-based ultrasound contrast agent (BY963). A transcranial Dopplersonography study. **1998**, 8, 83-7		5
40	Administration of modified spherosome suspension (BY963) leads to an increase of acoustic impedance in dog brain tissue. **1998**, 8, 164-8		4

39	Persistent opacification of the left ventricle and myocardium with a new echo contrast agent. *Ultrasound in Medicine and Biology*, **1999**, 25, 763-9	3.5	13
38	Acoustically stimulated transient power scattering explains enhanced detection of the very low velocities in myocardial capillaries by power Doppler imaging: an in vitro study. *Journal of the American Society of Echocardiography*, **1999**, 12, 643-9	5.8	18
37	Clinical applications of transpulmonary contrast echocardiography. *American Heart Journal*, **1999**, 137, 144-53	4.9	56
36	Advances in echocardiography. *Australian and New Zealand Journal of Medicine*, **2000**, 30, 360-6		2
35	Assessment of myocardial perfusion with contrast echocardiography at rest and with stress: an emerging technology. *Progress in Cardiovascular Diseases*, **2000**, 43, 245-58	8.5	14
34	Achieving tissue-level perfusion in the setting of acute myocardial infarction. *American Journal of Cardiology*, **2000**, 85, 39C-46C	3	21
33	Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. *American Journal of Cardiology*, **2000**, 86, 669-74	3	134
32	Contrast Echocardiography in Clinical Practice: Integration of Contrast Echocardiography. *Journal of Diagnostic Medical Sonography*, **2000**, 16, 97-102	0.4	
31	Inhibition of carotid artery neointimal formation with intravenous microbubbles. *Ultrasound in Medicine and Biology*, **2001**, 27, 259-65	3.5	43
30	Power Doppler dual-frame triggering of myocardial contrast echocardiography: a quantitative video intensity analysis. *Echocardiography*, **2001**, 18, 497-501	1.5	2
29	Pharmacokinetics of echocontrast agent infusion in a dog model. *Journal of Neuroimaging*, **2001**, 11, 298-302	2.8	9
28	Quantitative and qualitative analysis of in vivo Doppler signal enhancement of FS-069. *Investigative Radiology*, **2002**, 37, 1-6	10.1	3
27	Contrast echocardiography and medical economics: looking into the crystal ball. *European Heart Journal Supplements*, **2002**, 4, C39-C47	1.5	
26	Assessment of coronary stenoses of graded severity by myocardial contrast echocardiography. *Journal of the American Society of Echocardiography*, **2002**, 15, 197-205	5.8	6
25	Effect of destructive pulse duration on the detection of myocardial perfusion in myocardial contrast echocardiography: In vitro and in vivo observations. *Journal of the American Society of Echocardiography*, **2002**, 15, 1440-7	5.8	12
24	Weak concordance between wall motion and microvasculature status after acute myocardial infarction: study with myocardial contrast echocardiography in real time with power modulation. *European Journal of Echocardiography*, **2002**, 3, 89-94		7
23	Fluorous Materials for Biomedical Uses. **2004**, 521-573		14
22	Microbubbles: Basic Principles. **2004**, 19-43		3

21	Microvascular remodeling and accelerated hyperemia blood flow restoration in arterially occluded skeletal muscle exposed to ultrasonic microbubble destruction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 287, H2754-61	5.2	41
20	Ultrasound-microbubble-induced neovascularization in mouse skeletal muscle. *Ultrasound in Medicine and Biology*, **2005**, 31, 1411-22	3.5	32
19	WFUMB Safety Symposium on Ultrasound Contrast Agents: clinical applications and safety concerns. *Ultrasound in Medicine and Biology*, **2007**, 33, 180-6	3.5	34
18	Ultrasonic microbubble destruction stimulates therapeutic arteriogenesis via the CD18-dependent recruitment of bone marrow-derived cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 1117-22	9.4	25
17	Preparation of targeted microbubbles: ultrasound contrast agents for molecular imaging. *Medical and Biological Engineering and Computing*, **2009**, 47, 875-82	3.1	101
16	Coronary microcirculation changes during myocardial stunning in dogs. *Cardiology*, **2010**, 117, 68-74	1.6	5
15	Ultrasonic contrast agents. **2011**, 77-89		5
14	Ultrasound contrast agents: updated data on safety profile. *Current Pharmaceutical Design*, **2012**, 18, 2253-8	3.3	8
13	Ultrasound imaging in an animal model of vascular inflammation following balloon injury. *Ultrasound in Medicine and Biology*, **2012**, 38, 1552-8	3.5	
12	Molecular properties of lysozyme-microbubbles: towards the protein and nucleic acid delivery. *Amino Acids*, **2012**, 43, 885-96	3.5	14
11	20 years of ultrasound contrast agent modeling. *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, **2013**, 60, 7-20	3.2	105
10	Can Doppler or contrast-enhanced ultrasound analysis add diagnostically important information about the nature of breast lesions?. *Clinics*, **2014**, 69, 87-92	2.3	17
9	Microbubble Formulations: Synthesis, Stability, Modeling and Biomedical Applications. *Ultrasound in Medicine and Biology*, **2019**, 45, 301-343	3.5	41
8	Kinetics of albumin microbubble dissolution in aqueous media. *Soft Matter*, **2020**, 16, 2149-2163	3.6	7
7	Enhancing In Vitro Stability of Albumin Microbubbles Produced Using Microfluidic T-Junction Device. *Langmuir*, **2021**,	4	1
6	Direct video-microscopic observation of the dynamic effects of medical ultrasound on ultrasound contrast microspheres. *Investigative Radiology*, **1998**, 33, 863-70	10.1	36
5	Transient myocardial contrast after initial exposure to diagnostic ultrasound pressures with minute doses of intravenously injected microbubbles. Demonstration and potential mechanisms. *Circulation*, **1995**, 92, 2391-5	16.7	233
4	Relation between air-filled albumin microbubble and red blood cell rheology in the human myocardium. Influence of echocardiographic systems and chest wall attenuation. *Circulation*, **1996**, 94, 445-51	16.7	37

3	Characteristics of transcranial Doppler signal enhancement using a phospholipid-containing echocontrast agent. *Stroke*, **1997**, 28, 1006-8	6.7	4
2	Differential effects of selective and non-selective nitric oxide synthase inhibitors on the blood perfusion of ischemia-reperfused myocardium in dogs. *Medical Science Monitor Basic Research*, **2013**, 19, 181-6	3.2	5
1	Myocardial Contrast Stress Echocardiography. **2003**, 311-328		